Missed call costs HEC $50 million in Gilenya drug patent case

Missed call costs HEC  million in Gilenya drug patent case

A failed appeal of a preliminary injunction bail hearing cost HEC Pharm Co. its chance to recover $50 million in a patent lawsuit it ultimately won over HEC’s copycat Novartis SA The blockbuster multiple sclerosis drug Gilenya, a federal judge has ruled.

Judge Kent A. Jordan’s decision Tuesday in U.S. District Court for the District of Delaware denied HEC’s motion to recover damages. The ruling stems from a complex legal battle over infringement of U.S. Patent No. 9,187,405, which covers the Gilenya dosage regimen. Jordan found the patent valid and infringed after a trial in the lower court, …